MOLECULAR TEMPLATES INC
1 day chart
Molecular Templates, Inc. is a clinical stage biopharmaceutical company that is focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer and other serious diseases. The Company utilizes its biologic drug platform to design and generate engineered toxin bodies (ETBs). ETBs use a genetically engineered version of the Shiga-like Toxin A subunit (SLTA), a ribosome inactivating bacterial protein. The Company is developing ETBs for various targets, including CD20, CD38, HER2, and PD-L1. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of multiple myeloma. HER2 is clinically validated as a target for the treatment of solid tumors including breast and gastric cancer. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.
Buy US stocks in Australia with $0 brokerage and trade MTEM today!
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.